Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,798,872
  • Shares Outstanding, K 220,827
  • Annual Sales, $ 4,991 M
  • Annual Income, $ 2,404 M
  • 60-Month Beta 1.46
  • Price/Sales 4.97
  • Price/Cash Flow 9.62
  • Price/Book 2.12
  • Price/Earnings ttm 10.66
  • Earnings Per Share ttm 10.54
  • Most Recent Earnings 3.22 on 05/06/20
  • Next Earnings Date 07/22/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 2.29
  • Number of Estimates 10
  • High Estimate 2.43
  • Low Estimate 2.10
  • Prior Year 2.46
  • Growth Rate Est. (year over year) -6.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
107.39 +4.57%
on 06/12/20
120.50 -6.80%
on 06/08/20
-3.98 (-3.42%)
since 06/02/20
3-Month
88.92 +26.29%
on 04/03/20
121.50 -7.57%
on 06/01/20
+21.95 (+24.29%)
since 04/02/20
52-Week
72.67 +54.53%
on 03/16/20
134.84 -16.72%
on 07/03/19
-21.78 (-16.24%)
since 07/02/19

Most Recent Stories

More News
Why the Earnings Surprise Streak Could Continue for Alexion (ALXN)

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ALXN : 112.30 (-0.08%)
Gilead's Coronavirus Drug Being Stocked by the US Government

Gilead's (GILD) coronavirus drug, remdesivir, is being stocked by the Trump administration through September.

ALXN : 112.30 (-0.08%)
AZN : 53.80 (+0.90%)
RHHBY : 43.7900 (-0.55%)
GILD : 76.35 (+0.38%)
SEC Charges Alexion Pharmaceuticals With FCPA Violations

Washington, D.C.--(Newsfile Corp. - July 2, 2020) - The Securities and Exchange Commission today announced that Boston-based pharmaceutical company Alexion Pharmaceuticals Inc. has agreed to pay more than...

ALXN : 112.30 (-0.08%)
Alexion Completes Acquisition of Portola

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). The acquisition adds Factor Xa inhibitor reversal...

ALXN : 112.30 (-0.08%)
PTLA : 18.03 (+0.22%)
Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.

ALXN : 112.30 (-0.08%)
GILD : 76.35 (+0.38%)
VRTX : 291.10 (+1.68%)
ZGNX : 29.19 (+0.41%)
ICPT : 47.09 (+1.23%)
VXRT : 7.37 (-7.88%)
Gilead Prices Coronavirus Drug Remdesivir at $390 Per Vial

Gilead (GILD) prices experimental coronavirus drug, remdesivir, at $390 per vial.

ALXN : 112.30 (-0.08%)
RHHBY : 43.7900 (-0.55%)
GILD : 76.35 (+0.38%)
INCY : 106.47 (+3.72%)
ULTOMIRIS(R) (ravulizumab) Receives Marketing Authorization from European Commission for Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS)

--- ULTOMIRIS has the potential to become the new standard of care in Europe for the treatment of aHUS -

ALXN : 112.30 (-0.08%)
Investors Wary of the Weekend Again as Cases Rise

Investors Wary of the Weekend Again as Cases Rise

ALXN : 112.30 (-0.08%)
HPE : 9.41 (-0.11%)
PPC : 16.73 (+0.72%)
RGEN : 126.65 (+1.98%)
THO : 106.40 (+1.14%)
DG : 189.48 (-0.74%)
NTRA : 48.08 (-2.99%)
BIG : 40.37 (-1.03%)
SNX : 117.04 (-0.27%)
JPM : 92.66 (-0.64%)
BAC : 23.29 (+0.13%)
WFC : 25.34 (+1.00%)
C : 50.55 (+0.40%)
Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation

Gilead's (GILD) experimental coronavirus drug, remdesivir, has been recommended for approval by the EMA's human medicines committee.

ALXN : 112.30 (-0.08%)
RHHBY : 43.7900 (-0.55%)
GILD : 76.35 (+0.38%)
INCY : 106.47 (+3.72%)
Chart of the Day: Alexion Pharmaceuticals (ALXN)

Alexion Pharmaceuticals (ALXN) is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming...

ALXN : 112.30 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade ALXN with:

Business Summary

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes...

See More

Key Turning Points

2nd Resistance Point 115.61
1st Resistance Point 113.95
Last Price 112.30
1st Support Level 111.18
2nd Support Level 110.07

See More

52-Week High 134.84
Last Price 112.30
Fibonacci 61.8% 111.09
Fibonacci 50% 103.75
Fibonacci 38.2% 96.42
52-Week Low 72.67

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar